Aralez Pharma (ARLZ) Reports Q4 Loss of $0.48/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Aralez Reports Fourth Quarter And Full-Year 2016 Financial Results
March 13, 2017 6:30 AM EDT-4Q16 Net Revenues Increased to $20 Million Versus $6 Million in the Comparable Period of 2015-
-Full-Year Net Revenues Increased to $54.3 Million Versus $21.4 Million in the Comparable Period of 2015-
-Provides 2017 Full-Year Guidance-
MISSISSAUGA, Ontario, March 13, 2017 /PRNewswire/ --Â Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) (Aralez or the Company)Â today announced financial results for the fourth quarter and full-year ended December 31, 2016. The Company also highlighted certain recent corporate and commercial achievements. All figures are in U.S. dollars.
Recent Corporate Updates:... More
